Tecfidera Case Study: Using Safety as a Springboard for Blockbuster Status

STUDY OVERVIEW

When it was approved in March 2013, Tecfidera was the third oral drug for relapse remitting multiple sclerosis (MS). Yet Biogen's Tecfidera outperformed all other MS drugs in its first three months on the market. In its first four quarters on the market, Tecfidera generated $1.4 billion in sales.

How?

While Tecfidera's efficacy was comparable to its competitors, the new drug's safety profile was considered superior. Biogen used that advantage and also strategically priced Tecfidera so it was less than its main competitor Gilenya but more than the less popular Anbagio. This case study examines how Biogen used safety and pricing to differentiate Tecfidera from competitors and catapult the MS drug to blockbuster status.

KEY TOPICS

• Product Overview
• Safety Profile
• Launch Success
• Commercialization
• Global Market
• Next Challenge

• Tecfidera Physician Trial Rate 2013
• Tecfidera Quarterly Sales 2013
• Biogen MS Product Revenues 2013
• Tecfidera, Gilenya and Aubagio Pricing

Industries Profiled:
Biotech; Manufacturing; Health Care; Pharmaceutical; Biopharmaceutical; Clinical Research; Laboratories


Companies Profiled:
Biogen; Sanofi; Novartis

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.